Coalition Opposes Congressional Attempt to Stifle Lower-Priced Generic Drug Competition

A coalition of policy think tanks sent a letter to Congress warning them that proposed legislation would have severe adverse consequences on consumers by significantly impeding the market entry of generic drug manufacturers. These generic drug companies offer much lower-priced drug for patients because they compete against name brand products — sometimes saving patients 90% off of prescription drug purchases. Generic drugs have saved consumers over a trillion dollars in the last decade and Congress should be careful about reducing this essential source of market rivalry.

The entire coalition letter is available here.

FacebooktwitterredditlinkedinFacebooktwitterredditlinkedin